We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GE Healthcare Launches Biacore T200 for Characterization of Biomolecular Interactions

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
GE Healthcare, a unit of General Electric Company, announces the launch of Biacore™ T200, designed to deliver sensitivity in the measurement of high quality kinetic, affinity, concentration, specificity, and thermodynamic interaction data, in real time. The system builds upon the success of Biacore T100.

According to GE Healthcare, the performance, versatility and sensitivity of Biacore T200 enables analysis of interactions involving the smallest, low molecular weight compounds, interactions of rare targets, and facilitates the analysis of interactions involving G protein-coupled receptors.

The company says, the sensitivity of the system also allows antigen immobilization levels so low that interactions with antibody in solution can be analyzed, without avidity effects, thus adding flexibility to assay design. In addition, the system expands the range of kinetic parameters that can be studied with precision and confidence.

Guided workflows and the ability to analyze up to 384 samples in unattended runs facilitates data acquisition for a large range of biomolecular interaction studies, including defining potential drug targets and diagnostic markers, and time- and cost-efficient concentration analysis in vaccine development. Calibration-free concentration analysis enables highly reproducible, precise measurement of active protein concentration, whether or not a standard is available.

Dr. Johan Weigelt, SGC, Karolinska Institutet, commented: “The high sensitivity and information-rich data of Biacore T200 allowed us to assess inhibitor selectivity and identify weak binders not possible with our alternative technology. The findings are of great value as a starting point for development of selective inhibitors of novel PARP enzymes.”

Biacore T200 software also provides support for immunogenicity testing, for detection and characterization of anti-drug antibodies during preclinical and clinical development. The optional GxP Package enables Biacore T200 to integrate seamlessly into GxP-regulated workflows.